Baxter International (BAX) Stock Price
Baxter International Price
Over the last 19 years Baxter International grew revenue by 0.4% annually, reaching 11.24 B USD. Earnings per share have grown at 5.5% per year over the last 17 years. For Baxter International, the net margin of -8.5% is down versus 10.6% a few years ago. At today's price the dividend yield works out to roughly 2.15%. The consensus 12-month price target for Baxter International is 25.00 USD, about 3.5% above where the stock trades today. Of 20 analysts, 5 rate the stock a buy — an overall Hold consensus.
Baxter International stock price
Baxter International business model & stock analysis
Frequently asked questions about Baxter International
The business model of Baxter International Inc. is centered around developing, manufacturing, and marketing a broad portfolio of products and therapies for patients with life-threatening medical conditions. Baxter provides essential healthcare solutions across the clinical areas of critical care, nutrition, renal, and pharmaceuticals. The company's products and services aim to support healthcare professionals in improving patient outcomes and enhancing overall medical care. Baxter International Inc. operates globally and collaborates with various stakeholders in the healthcare industry to deliver innovative solutions that address unmet medical needs.
Baxter International Inc is primarily active in the healthcare industry. As a global leader in medical technology, Baxter specializes in providing innovative solutions for hospitals, clinics, and home care settings. The company focuses on various segments within healthcare, including renal care, acute therapies, and medication delivery. With a wide range of products and services, Baxter plays a vital role in enhancing patient care and improving outcomes across the healthcare continuum.
The main competitors of Baxter International Inc in the market include Johnson & Johnson, Fresenius Medical Care AG & Co. KGaA, and Becton, Dickinson and Company.
Baxter International Inc., based in Deerfield, Illinois, is a renowned American healthcare company with a rich history and impressive background. Established in 1931, Baxter has consistently excelled in developing and manufacturing medical products and technologies, specializing in biotherapeutics, renal care, and medication delivery. With a commitment to advancing patient care, Baxter has grown to become a global leader in the healthcare industry. Over the years, the company has introduced numerous innovative and life-saving solutions, including intravenous therapies, vaccines, and devices for dialysis. With its dedication to meeting critical healthcare needs worldwide, Baxter International Inc. continues to be a prominent player in the medical field.
Over the years, Baxter International Inc has achieved numerous significant milestones, solidifying its position in the healthcare industry. One notable achievement is the development of innovative medical products and therapies that have improved patient outcomes globally. Baxter International Inc has also demonstrated its commitment to sustainability by implementing eco-friendly practices and receiving recognition for its environmental efforts. Additionally, the company has expanded its international presence through strategic acquisitions and collaborations, further strengthening its global footprint. Overall, Baxter International Inc's dedication to innovation, sustainability, and global expansion has propelled it to become a leading player in the healthcare sector.
Baxter International Inc is primarily present in numerous countries and regions globally. This healthcare company operates in North America, including the United States, Canada, and Mexico. It has a strong presence in Europe, spanning countries like Germany, France, Italy, and the United Kingdom. Baxter International Inc also has significant operations in the Asia-Pacific region, with a focus on countries such as China, Japan, India, and Australia. Additionally, the company maintains a presence in Latin America, including Brazil, Argentina, and Chile. With its extensive global reach, Baxter International Inc serves a diverse range of markets and communities worldwide.
Baxter International Inc represents values of integrity, innovation, and collaboration. With a corporate philosophy focused on improving patient outcomes, the company strives to provide high-quality healthcare products and services worldwide. Baxter International Inc is committed to advancing medicine through its diverse portfolio of medical devices, pharmaceuticals, and biotechnology solutions. As a global leader, Baxter International Inc consistently emphasizes ethical practices, regulatory compliance, and sustainability. By actively investing in research and development, Baxter International Inc aims to drive positive changes in healthcare and enhance the well-being of patients globally.
Analysts currently set an average price target of 25.00 USD for the Baxter International stock (median: 25.00 USD), implying +3.5 % versus the latest price. The consensus is based on 20 analyst ratings.
20 analysts currently rate the Baxter International stock: 5 recommend buying, 14 holding and 1 selling. For 2026, analysts expect Baxter International to generate revenue of 11.62 B USD and earnings per share of 2.04 USD.
Converted at the current exchange rate, the Baxter International share trades at 21.56 EUR (24.15 USD).
The Baxter International share (BAX) is listed on 11 stock exchanges, including: NYSE (BAX), London (0QK8.L), SIX (Zürich) (BAX.SW), XETRA (BTL.DE), Frankfurt (BTL.F), München (BTL.MU), Düsseldorf (BTL.DU), Hamburg (BTL.HM).
Baxter International Inc is a US-based company operating in the healthcare and pharmaceutical sectors. The company provides medical products and services to supply patients worldwide. It is divided into three main business segments: Hospital Products, Renal Products, and Clinical Nutrition. Hospital Products is the largest segment and offers a variety of products including infusion solutions, injectables, medical devices, and concentrated solutions. Renal Products includes products and services for dialysis treatment, home hemodialysis, and acute kidney failure. Baxter also manufactures dialysis machines and accessories, as well as dialysis containers and concentrates. Clinical Nutrition also offers specialized nutrition products and preparations for parenteral nutrition. The company is a leading provider of parenteral nutrition products, including amino acids, carbohydrates, fat emulsions, and electrolytes. Baxter International also manufactures blood products such as plasma products and clotting factors. Additionally, the company offers specially processed biological products that can be used to treat conditions such as hemophilia and immunodeficiency. The company also operates an advanced life sciences business focused on drug development and medical devices. Baxter International collaborates with numerous global partners and develops innovative technologies in oncology and other areas of medical research. Baxter International is a company focused on proactive solutions to improve patient care and provide safe, effective, and high-quality medical products. The company is also committed to sustainable development and environmental protection by optimizing its materials and energy sources and continuously improving its production technology. In summary, Baxter International is a company dedicated to the development and provision of high-quality medical products and services. Through its various business segments, the company offers a wide range of products and services for different medical conditions to improve the medical care of patients worldwide. The company has also committed to sustainable and environmentally friendly production to fulfill its responsibility to society and the environment.
The expected revenue of Baxter International is 11.62 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Baxter International is 1.05 B USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Baxter International is currently 11.85. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Baxter International stock.
The price-to-sales ratio (P/S) of Baxter International is currently 1.07. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Baxter International stock.
The Eulerpool Quality Score for Baxter International is 1/10.
The ISIN of Baxter International is US0718131099. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Baxter International is 853815. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Baxter International is BAX. The ticker symbol is used to trade Baxter International shares on the stock exchange.
Baxter International stock
Baxter International Peer Group
Baxter International Ticker
Baxter International FIGI
All fundamentals and in-depth analysis of Baxter International
Our stock analysis for Baxter International stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Baxter International. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.